title: [Determination of biomarkers in exhaled breath condensation of acute exacerbation of chronic obstructive pulmonary disease and its clinical implications].
abstract: Objective:To analyse the changes and clinical implication of biomarkers in exhaled breath condensates (EBC) of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) before and after treatment.Methods:20 patients with AECOPD were enrolled, including 15 males and 5 females. The average age was 71±10, ranging from 50-85. The concentrations of Leukotriene B4 (LTB4) and Interleukin 6 (IL-6) from EBC were assayed by ELISA kit before and after treatment. Serum inflammatory indexes, pulmonary function test and quality of life (CAT) were observed at the same time, the relationship between EBC biomarkers and clinical markers were investigated.Results:The concentration of LTB4 and IL-6 of AECOPD patients with treated [(20.79±2.27)ng/L, (0.39±0.18)ng/L, respectively], were significantly lower compared with that before treatment [(22.64±3.01)ng/L, (0.60±0.36)ng/L,P<0.05, respectively]. The percentage of neutrophils, CRP were decreased after treatment. But no correlation was found between LTB4, IL-6 and serum inflammatory indexes, pulmonary function or CAT(P>0.05).Conclusion:The concentration of biomarkers (LTB4, IL-6) in EBC of AECOPD patients can dynamically monitor the inflammation in respiratory tract and evaluate the therapeutic effect.
authors.affiliation: Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Zhejiang University, Zhejiang 310003, China.
authors.forename: X Q
authors.initials: XQ
authors.lastname: Dong
authors.forename: Q
authors.initials: Q
authors.lastname: Shen
authors.forename: Y N
authors.initials: YN
authors.lastname: Yao
authors.forename: J J
authors.initials: JJ
authors.lastname: Chen
authors.forename: G H
authors.initials: GH
authors.lastname: Lu
authors.forename: J Y
authors.initials: JY
authors.lastname: Zhou
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001944:Breath Tests; D004797:Enzyme-Linked Immunosorbent Assay; D045853:Exhalation / Q000502:physiology*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D007975:Leukotriene B4 / Q000378:metabolism*; D008168:Lung / Q000187:drug effects / Q000276:immunology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D029424:Pulmonary Disease, Chronic Obstructive / Q000276:immunology / Q000378:metabolism* / Q000523:psychology; D011788:Quality of Life; D012129:Respiratory Function Tests; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; C508600:IL6 protein, human; D015850:Interleukin-6; D007975:Leukotriene B4
keywords: Exhaled breath condensate; Pulmonary disease, chronic obstructive; Pulmonary function test